ENHERTU fam-trastuzumab deruxtecan-nxki and not trastuzumab or ado-trastuzumab emtansine. Persons with disabilities having problems accessing the PDF files below may call 301 796-3634 for assistance.
Enhertu Approved In The U S For The Treatment Of Patients With Previously Treated Her2 Positive Advanced Gastric Cancer Biospace
Individuals using assistive technology may not be able to fully access the information contained in this file.
Enhertu package insert. Enhertu is a brand-name prescription drug. ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. ENHERTU fam-trastuzumab deruxtecan-nxki POLICY I.
DrugsFDA information available about ENHERTU. Enhertu 100 mg single-dose vial. Follow applicable special handling and disposal procedures.
For assistance please send an e- mail to. ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. VYONDYS 53 is a drug for the treatment of a particular type of Duchenne muscular dystrophy DMD.
A package insert typically includes information regarding specific indications administration schedules dosing side effects contraindications results from some clinical. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. Referenced with permission from the NCCN Drugs Biologics Compendium NCCN Compendium fam-trastuzumab deruxtecan.
It is to be used only in patients who have a. Enhertu approved in Japan for treatment of patients with HER2 positive unresectable or metastatic breast cancer. Withhold TRODELVY for absolute neutrophil count below 1500mm.
Reconstitute and further dilute ENHERTU prior to intravenous infusion. HER2 means the cancer cells have abnormally high levels of a protein. See full prescribing information.
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL. A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. Enhertu fam-trastuzumab deruxtecan is a member of the HER2 inhibitors drug class and is commonly used for Breast Cancer Breast Cancer - Metastatic and Stomach Cancer.
NEUTROPENIA AND DIARRHEA Severe neutropenia may occur. Approval Letter s PDF Printed Labeling PDF Date. FDA-Approved Indications Breast Cancer.
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PREVNAR 13 safely and effectively. ENHERTU fam-trastuzumab deruxtecan-nxki is a cytotoxic drug. Its FDA-approved to treat HER2-positive HER2 breast cancer in women and men.
FDA Approval Letter and Labeling. Use appropriate aseptic technique. This indication is approved under accelerated approval based on tumor response rate and duration of response see Clinical Studies 141.
This indication is approved under accelerated approval based on tumor response rate and duration of response see Clinical Studies 141.
